You just read:

Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)

News provided by

Daiichi Sankyo Company, Limited

08 Dec, 2018, 13:00 GMT